Brief: Aura Biosciences To Present Phase 2 Safety Data Evaluating Suprachoroidal Administration Of Belzupacap Sarotalocan (Au-011) In Patients With Choroidal Melanoma At Esmo 2022 Congress
07/09/2022 12:24
Sept 7 (Reuters) - Aura Biosciences Inc AURA.O :
* AURA BIOSCIENCES TO PRESENT PHASE 2 SAFETY DATA EVALUATING
SUPRACHOROIDAL ADMINISTRATION OF BELZUPACAP SAROTALOCAN (AU-011)
IN PATIENTS WITH CHOROIDAL MELANOMA AT ESMO 2022 CONGRESS
Source text for Eikon: ID:nBw2DzyG7a
Further company coverage: AURA.O
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs